WithdrawnNCT02492074

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study

Medication studyAges 18–45GermanySchizophrenia

The study in practice

Understand this study

Listed age limits: 18 years to 45 years.

Listed locations: Mannheim, GermanySee all locations and recruitment
Activities: Medication described in the protocol · Medication and placebo comparator listed across study groups
Compensation: Payment and expense reimbursement have not been verified.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateEstimated: December 2024

Recruitment status: Withdrawn
Enrollment listed in the registry: 0
Sponsor: Central Institute of Mental Health, Mannheim
Sponsor type: Research institute
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Germany
Age range: From 18 Years to 45 Years
Official registry ID: NCT02492074
Official title: Show the full official title
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System and Brain Function

The HopeStage team will email you.

Withdrawn

Mannheim

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Central Institute of Mental Health, Mannheim, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Delta-9-tetrahydrocannabinol, Cannabidiol and Placebo.

Who can participate?

Listed age limits: 18 years to 45 years.

Is this study still recruiting?

The registry lists this study as withdrawn.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.